drugset
drugset / Trial / NCT02674581

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

NCT02674581 ↗

Phase 1 Completed 30 enrolled ViiV Healthcare GlaxoSmithKline · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An oral dose in healthy and renally impaired subjects to determine the drug effect for BMS-663068.

Timeline

Start
2016-02-26
Primary completion
2016-05-24
Completion
2016-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Fostemsavir Other / unclassified — Oral

Indications

HIV infectious disease